Connect with us
The main European stock markets opened this Wednesday with mixed trends. Specifically, Paris and London lost 0.1% and 0.05%, respectively, while Milan and Frankfurt rose 0.16%...
Grifols' guidance for 2024 estimates recording an adjusted EBITDA of more than 1.8 billion euros, as well as a free cash flow of five million euros....
Of the Spanish pharma listed companies, PharmaMar has suffered the most significant drop in profits due to generic drug competition with its star drug. Rovi has...
Vytrus Biotech projects that by 2027, 60% of its revenue will be derived from its current plant stem cell business, with the remaining 40% coming from...
Oryzon Genomics reduces losses by 20.7% in 2023, reporting over 3.3 million euros compared to the previous year's 4.2 million. Income falls by nearly 28%, standing...
The partnership with Moderna has been very fruitful for Rovi: the laboratory has gone from earning 65.6 million euros in third-party manufacturing in 2019 to billing...
Nina Capital registers a third financing vehicle with fifty million euros, focusing on investments between 200,000 and two million euros in series A and early phases....
There are many companies in the biomedical sector that, being in the investment or expansion phase, have negative or reduced quotas. Given this particularity, what monetization...
This counterattack by Gotham comes weeks after Grifols has received accolades following the confirmation of the sale to Haier of its 20% stake in Shanghai Raas...
Ailin secures 1.5 million euros in its first financing round, surpassing initial expectations. Investors include a family office in the health sector, Business Angels, and healthcare-related...
 |
|
 |  |
 |
|